Alendronate increases BMD at appendicular and axial skeletons in patients with established osteoporosis

Table 3 Bone formation and resorption markers. Bone Alkaline Phosphate (BALP) and Deoxypyridinoline (DPD) level in patients with established osteoporosis compared between Alendronate group (ALN) (n = 22) and placebo control group (CON) (n = 25) at baseline and follow-up at 6- and 12 months (Data: mean ± SD)

Biochemical Markers	Group	Baseline	6-month	12-month	% difference⁺
BALP	ALN	62.27 ± 16.86	40.33 ± 9.98 **	34.35 ± 9.87 **	-39.9 ± 33.6^a
	CON	66.17 ± 14.91	56.72 ± 18.24 **	55.13 ± 15.76 **	-16.7 ± 14.5
DPD	ALN	50.82 ± 35.10	25.11 ± 18.65 **	23.03 ± 14.72 **	-42.6 ± 30.4^b
	CON	33.70 ± 20.28	40.11 ± 36.92	27.28 ± 10.95	-9.4 ± 26.7

+: percentage difference compared between baseline and 12-month
a: p < 0.01; b: p < 0.05: significant difference in BALP found between ALN and CON group (independent t-test)
*p < 0.05; ** p < 0.01: compared with baseline (paired t-test)

ISSN: 1749-799X